176 related articles for article (PubMed ID: 29462482)
1. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT).
Nakachi K; Konishi M; Ikeda M; Mizusawa J; Eba J; Okusaka T; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2018 Apr; 48(4):392-395. PubMed ID: 29462482
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K; Ikeda M; Konishi M; Nomura S; Katayama H; Kataoka T; Todaka A; Yanagimoto H; Morinaga S; Kobayashi S; Shimada K; Takahashi Y; Nakagohri T; Gotoh K; Kamata K; Shimizu Y; Ueno M; Ishii H; Okusaka T; Furuse J;
Lancet; 2023 Jan; 401(10372):195-203. PubMed ID: 36681415
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
Nakachi K; Konishi M; Ikeda M; Shimada K; Okusaka T; Saiura A; Ishii H; Sugiyama M; Furuse J; Sakamoto H; Shimamura T; Ohta T
Int J Clin Oncol; 2018 Oct; 23(5):894-899. PubMed ID: 29705976
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Mizusawa J; Morizane C; Okusaka T; Katayama H; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2016 Apr; 46(4):385-8. PubMed ID: 27025903
[TBL] [Abstract][Full Text] [Related]
6. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.
Yoshida M; Yanagimoto H; Tsugawa D; Akita M; Urade T; Nanno Y; Fukushima K; Gon H; Komatsu S; Asari S; Kido M; Toyama H; Ajiki T; Fukumoto T
Am Surg; 2024 Jun; 90(6):1279-1289. PubMed ID: 38226586
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
Ikeda M; Ohno I; Ueno H; Mitsunaga S; Hashimoto Y; Okusaka T; Kondo S; Sasaki M; Sakamoto Y; Takahashi H; Hara R; Kobayashi S; Nakamura O; Morizane C
Invest New Drugs; 2019 Feb; 37(1):109-117. PubMed ID: 29995287
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1.
Hisashige A; Sasako M; Nakajima T
BMC Cancer; 2013 Oct; 13():443. PubMed ID: 24079752
[TBL] [Abstract][Full Text] [Related]
11. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
[TBL] [Abstract][Full Text] [Related]
12. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
13. ASO Author Reflections: Phase II Trial of Adjuvant Chemotherapy with S-1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
Ebata T; Mizuno T
Ann Surg Oncol; 2020 Jul; 27(7):2357-2358. PubMed ID: 32206952
[No Abstract] [Full Text] [Related]
14. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
17. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
18. [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):].
Oki E; Kakeji Y; Yoshida R; Ikeda K; Nishida K; Koga T; Egashira A; Tokunaga E; Morita M; Baba H; Maehara Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():138-43. PubMed ID: 16897990
[TBL] [Abstract][Full Text] [Related]
19. S-1 monotherapy in patients with advanced biliary tract cancer.
Sasaki T; Isayama H; Yashima Y; Yagioka H; Kogure H; Arizumi T; Togawa O; Matsubara S; Ito Y; Nakai Y; Sasahira N; Hirano K; Tsujino T; Tada M; Kawabe T; Omata M
Oncology; 2009; 77(1):71-4. PubMed ID: 19556812
[TBL] [Abstract][Full Text] [Related]
20. [Present state and prospects of adjuvant chemotherapy for gastric cancer].
Hori T; Ozawa R; Hanayama H; Yamashita H; Kaibe N; Matsumoto T; Oshima T; Takemura M; Kikuchi S; Sasako M
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1390-5. PubMed ID: 21918333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
